Schizophrenia - Pipeline Review, H2 2016

Date: November 9, 2016
Pages: 349
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S2CB504A9C4EN
Leaflet:

Download PDF Leaflet

Schizophrenia - Pipeline Review, H2 2016
Schizophrenia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia – Pipeline Review, H2 2016, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 10, 13, 30, 1, 53, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 8 and 2 molecules, respectively.Schizophrenia.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Schizophrenia Overview
Therapeutics Development
Schizophrenia - Therapeutics under Development by Companies
Schizophrenia - Therapeutics under Investigation by Universities/Institutes
Schizophrenia - Pipeline Products Glance
Schizophrenia - Products under Development by Companies
Schizophrenia - Products under Investigation by Universities/Institutes
Schizophrenia - Companies Involved in Therapeutics Development
Schizophrenia - Therapeutics Assessment
Drug Profiles
Schizophrenia - Dormant Projects
Schizophrenia - Discontinued Products
Schizophrenia - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Schizophrenia, H2 2016
Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Investigation by Universities/Institutes, H2 2016
Schizophrenia - Pipeline by Adamed Sp. z o.o., H2 2016
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H2 2016
Schizophrenia - Pipeline by AgeneBio Inc., H2 2016
Schizophrenia - Pipeline by Alkermes Plc, H2 2016
Schizophrenia - Pipeline by Angita B.V., H2 2016
Schizophrenia - Pipeline by Astellas Pharma Inc., H2 2016
Schizophrenia - Pipeline by Athersys, Inc., H2 2016
Schizophrenia - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
Schizophrenia - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016
Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
Schizophrenia - Pipeline by BioCrea GmbH, H2 2016
Schizophrenia - Pipeline by BioHealthonomics Inc, H2 2016
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H2 2016
Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H2 2016
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H2 2016
Schizophrenia - Pipeline by Curemark, LLC, H2 2016
Schizophrenia - Pipeline by Delpor, Inc., H2 2016
Schizophrenia - Pipeline by Denovo Biopharma, LLC, H2 2016
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H2 2016
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H2 2016
Schizophrenia - Pipeline by Evotec AG, H2 2016
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
Schizophrenia - Pipeline by Galenea Corp., H2 2016
Schizophrenia - Pipeline by GeNeuro SA, H2 2016
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016
Schizophrenia - Pipeline by GP Pharm, S.A., H2 2016
Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H2 2016
Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2016
Schizophrenia - Pipeline by Heptares Therapeutics Limited, H2 2016
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016
Schizophrenia - Pipeline by Indivior Plc, H2 2016
Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H2 2016
Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
Schizophrenia - Pipeline by IntelGenx Corp., H2 2016
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H2 2016
Schizophrenia - Pipeline by Johnson & Johnson, H2 2016
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H2 2016
Schizophrenia - Pipeline by KemPharm, Inc., H2 2016
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2016
Schizophrenia - Pipeline by Lohocla Research Corporation, H2 2016
Schizophrenia - Pipeline by Luye Pharma Group Ltd., H2 2016
Schizophrenia - Pipeline by Mapi Pharma Ltd., H2 2016
Schizophrenia - Pipeline by Merck & Co., Inc., H2 2016
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H2 2016
Schizophrenia - Pipeline by NeurOp, Inc, H2 2016
Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
Schizophrenia - Pipeline by Omeros Corporation, H2 2016
Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Schizophrenia - Pipeline by Peptron, Inc., H2 2016
Schizophrenia - Pipeline by Pfizer Inc., H2 2016
Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H2 2016
Schizophrenia - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
Schizophrenia - Pipeline by Richter Gedeon Nyrt., H2 2016
Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Schizophrenia - Pipeline by Suven Life Sciences Ltd., H2 2016
Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2016
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
Schizophrenia - Pipeline by Vitality Biopharma Inc, H2 2016
Schizophrenia - Pipeline by VLP Therapeutics, LLC, H2 2016
Schizophrenia - Pipeline by Zogenix, Inc., H2 2016
Schizophrenia - Pipeline by Zysis Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Schizophrenia - Dormant Projects, H2 2016
Schizophrenia - Dormant Projects (Contd..1), H2 2016
Schizophrenia - Dormant Projects (Contd..2), H2 2016
Schizophrenia - Dormant Projects (Contd..3), H2 2016
Schizophrenia - Dormant Projects (Contd..4), H2 2016
Schizophrenia - Dormant Projects (Contd..5), H2 2016
Schizophrenia - Dormant Projects (Contd..6), H2 2016
Schizophrenia - Dormant Projects (Contd..7), H2 2016
Schizophrenia - Dormant Projects (Contd..8), H2 2016
Schizophrenia - Dormant Projects (Contd..9), H2 2016
Schizophrenia - Dormant Projects (Contd..10), H2 2016
Schizophrenia - Dormant Projects (Contd..11), H2 2016
Schizophrenia - Dormant Projects (Contd..12), H2 2016
Schizophrenia - Dormant Projects (Contd..13), H2 2016
Schizophrenia - Discontinued Products, H2 2016
Schizophrenia - Discontinued Products (Contd..1), H2 2016
Schizophrenia - Discontinued Products (Contd..2), H2 2016
Schizophrenia - Discontinued Products (Contd..3), H2 2016

LIST OF FIGURES

Number of Products under Development for Schizophrenia, H2 2016
Number of Products under Development for Schizophrenia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Adamed Sp. z o.o. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 28 pages
Galenea Corp. - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 21 pages
Evotec AG - Product Pipeline Review - 2016 US$ 1,275.00 Apr, 2016 · 60 pages

Ask Your Question

Schizophrenia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: